Literature DB >> 6416479

Acute hypotensive response to nifedipine added to prazosin in treatment of hypertension.

L D Jee, L H Opie.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6416479      PMCID: PMC1549987          DOI: 10.1136/bmj.287.6404.1514

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


× No keyword cloud information.
  3 in total

1.  Short- and long-term efficacy of a calcium-antagonistic agent (nifedipine) combined with methyldopa in the treatment of severe hypertension.

Authors:  M D Guazzi; C Fiorentini; M T Olivari; A Bartorelli; G Necchi; A Polese
Journal:  Circulation       Date:  1980-05       Impact factor: 29.690

2.  Adverse interaction between nifedipine and beta-blockade.

Authors:  L H Opie; D A White
Journal:  Br Med J       Date:  1980-11-29

3.  Antihypertensive effects of nifedipine combined with cardioselective beta-adrenergic receptor antagonism by atenolol.

Authors:  L H Opie; L Jee; D White
Journal:  Am Heart J       Date:  1982-09       Impact factor: 4.749

  3 in total
  15 in total

Review 1.  Nifedipine interactions in hypertensive patients.

Authors:  A Salvetti; A Magagna; B Abdel-Haq; M Lenzi; R Giovannetti
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 2.  Pharmacokinetic interactions with calcium channel antagonists (Part II).

Authors:  K D Schlanz; S A Myre; M B Bottorff
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

Review 3.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 4.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

5.  The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin.

Authors:  R Donnelly; H L Elliott; P A Meredith; C A Howie; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 6.  Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists.

Authors:  R Donnelly; H L Elliott; P A Meredith
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

7.  The influence of alpha 1-adrenergic blockade on the acute antihypertensive effect of nifedipine.

Authors:  H E Sluiter; F T Huysmans; T A Thien; R A Koene
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 8.  Choosing the correct drug for the individual hypertensive patient.

Authors:  L H Opie
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 9.  Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

10.  Addition of chlorthalidone to slow-release nifedipine in the treatment of arterial hypertension: a controlled study versus placebo.

Authors:  L A Ferrara; T Marotta; F Pasanisi; P Mastranzo; M Mancini
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.